AQST vs EMBC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AQST exhibits severe financial distress despite modest revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports massive negative profitability metrics, including a -188.09% profit margin and -33.92% ROA, with no meaningful earnings or cash flow generation. Insider selling totaling $1.86M over six months, including significant sales by top executives, signals deep skepticism about future prospects. While the stock trades below its 52-week high and has a strong analyst consensus, the lack of intrinsic value support and deteriorating earnings trends undermine long-term viability. The absence of a valid Altman Z-Score and Graham Number further limits fundamental valuation reliability.
EMBC shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 8/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AQST vs EMBC: Head-to-Head Comparison
This page compares Aquestive Therapeutics, Inc. (AQST) and Embecta Corp. (EMBC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.